$0.85
+0.07
(+8.52%)▲
9.41%
Downside
Day's Volatility :12.8%
Upside
3.74%
11.76%
Downside
52 Weeks Volatility :96.77%
Upside
96.34%
Period | Genetic Technologies Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -64.65% | 0.0% |
6 Months | -62.61% | 0.0% |
1 Year | -81.48% | 0.0% |
3 Years | -95.71% | -20.2% |
Market Capitalization | 2.7M |
Book Value | $0.04 |
Earnings Per Share (EPS) | -0.15 |
PEG Ratio | 0.0 |
Wall Street Target Price | 12.5 |
Profit Margin | -124.08% |
Operating Margin TTM | -105.96% |
Return On Assets TTM | -52.71% |
Return On Equity TTM | -160.47% |
Revenue TTM | 10.2M |
Revenue Per Share TTM | 2.73 |
Quarterly Revenue Growth YOY | -2.1% |
Gross Profit TTM | 6.0M |
EBITDA | -9.9M |
Diluted Eps TTM | -0.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 1370.59%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 189.3K | ↓ 63.5% |
Net Income | -5.5M | ↓ 34.98% |
Net Profit Margin | -2.9K% | ↓ 1266.28% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 17.9K | ↓ 86.56% |
Net Income | -4.8M | ↑ 25.06% |
Net Profit Margin | -26.9K% | ↓ 23968.33% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.8K | ↓ 61.23% |
Net Income | -4.4M | ↓ 7.74% |
Net Profit Margin | -63.9K% | ↓ 37054.55% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 90.4K | ↑ 1122.16% |
Net Income | -5.4M | ↑ 14.34% |
Net Profit Margin | -6.0K% | ↑ 57930.93% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 4.7M | ↑ 5536.33% |
Net Income | -4.9M | ↓ 1.07% |
Net Profit Margin | -104.95% | ↑ 5874.06% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 5.8M | ↑ 27.83% |
Net Income | -7.8M | ↑ 64.79% |
Net Profit Margin | -135.28% | ↓ 30.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.6M | ↓ 47.53% |
Net Income | -1.8M | ↓ 15.99% |
Net Profit Margin | -109.69% | ↓ 41.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.8M | ↑ 66.9% |
Net Income | -3.7M | ↑ 100.0% |
Net Profit Margin | -131.45% | ↓ 21.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8M | ↓ 35.36% |
Net Income | -2.1M | ↓ 42.4% |
Net Profit Margin | -117.14% | ↑ 14.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.0M | ↑ 68.79% |
Net Income | -4.2M | ↑ 100.0% |
Net Profit Margin | -138.8% | ↓ 21.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.4M | ↓ 46.24% |
Net Income | -3.2M | ↓ 48.98% |
Net Profit Margin | -131.73% | ↑ 7.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.0M | ↑ 62.47% |
Net Income | -6.4M | ↑ 100.0% |
Net Profit Margin | -162.16% | ↓ 30.43% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 6.2M | ↓ 49.08% |
Total Liabilities | 1.5M | ↓ 4.91% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.3M | ↓ 47.05% |
Total Liabilities | 1.0M | ↑ 2.73% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 10.8M | ↑ 378.8% |
Total Liabilities | 1.8M | ↑ 75.23% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 17.2M | ↑ 46.94% |
Total Liabilities | 1.1M | ↓ 45.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 14.3M | ↓ 9.45% |
Total Liabilities | 3.0M | ↑ 203.8% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 9.9M | ↓ 28.58% |
Total Liabilities | 2.5M | ↓ 15.49% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.2M | ↓ 24.55% |
Total Liabilities | 3.0M | ↑ 6.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.7M | ↑ 0.0% |
Total Liabilities | 3.2M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.0M | ↓ 5.34% |
Total Liabilities | 2.5M | ↓ 20.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.9M | ↑ 0.0% |
Total Liabilities | 2.5M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.5M | ↓ 43.01% |
Total Liabilities | 3.7M | ↓ 1.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.5M | ↑ 0.0% |
Total Liabilities | 3.7M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.6M | ↓ 17.5% |
Investing Cash Flow | 12.8K | ↓ 108.95% |
Financing Cash Flow | -10.0K | ↓ 100.14% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↑ 8.04% |
Investing Cash Flow | -368.4K | ↓ 4186.81% |
Financing Cash Flow | 2.2M | ↓ 31477.72% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.9M | ↓ 5.95% |
Investing Cash Flow | 44.7K | ↓ 112.35% |
Financing Cash Flow | 12.7M | ↑ 487.31% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↑ 14.77% |
Investing Cash Flow | -561.4K | ↓ 1255.64% |
Financing Cash Flow | 10.5M | ↓ 24.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.5M | ↓ 0.06% |
Investing Cash Flow | -2.4M | ↑ 362.29% |
Financing Cash Flow | -192.0K | ↓ 102.0% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.6M | ↑ 51.61% |
Investing Cash Flow | -208.0K | ↓ 90.99% |
Financing Cash Flow | 4.2M | ↓ 2364.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.9M | ↓ 11.17% |
Investing Cash Flow | -139.6K | ↑ 0.0% |
Financing Cash Flow | -113.5K | ↑ 100.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -691.2K | ↓ 62.22% |
Investing Cash Flow | 32.8K | ↓ 123.83% |
Financing Cash Flow | 4.2M | ↓ 3896.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.7M | ↑ 154.75% |
Investing Cash Flow | 32.5K | ↑ 0.0% |
Financing Cash Flow | -42.4K | ↓ 101.01% |
Sell
Neutral
Buy
Genetic Technologies Ltd is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Genetic Technologies Ltd | -44.48% | -62.61% | -81.48% | -95.71% | -93.81% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Genetic Technologies Ltd | NA | NA | 0.0 | 0.0 | -1.6 | -0.53 | NA | 0.04 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Genetic Technologies Ltd | NA | $2.7M | -93.81% | NA | -124.08% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Genetic Technologies Ltd
Revenue is up for the last 2 quarters, 2.43M → 3.95M (in $), with an average increase of 38.5% per quarter
Netprofit is down for the last 2 quarters, -3.20M → -6.41M (in $), with an average decrease of 100.0% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 86.6%
In the last 3 years, Genetic Technologies Ltd has experienced a drawdown of -95.7%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 85.5%
Susquehanna International Group, LLP
Morgan Stanley - Brokerage Accounts
BNP Paribas Arbitrage, SA
Rhumbline Advisers
UBS Group AG
genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.
Organization | Genetic Technologies Ltd |
Employees | 60 |
CEO | Mr. Simon Morriss |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.85
+8.52%
Keyarch Acquisition Corp
$0.85
+8.52%
Connexa Sports Technologies Inc
$0.85
+8.52%
Us Value Etf
$0.85
+8.52%
First Wave Biopharma Inc
$0.85
+8.52%
Global X Msci Next Emerging
$0.85
+8.52%
Fat Projects Acquisition Corp
$0.85
+8.52%
Capital Link Global Fintech
$0.85
+8.52%
Applied Uv Inc
$0.85
+8.52%